Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome

Published:2016-08-11 Issue:4 Volume:58 Page:969-978
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zhang Zheng,Chang Chun-Kang,He Qi,Guo Juan,Tao Ying,Wu Ling-Yun,Xu Feng,Wu Dong,Zhou Li-Yu,Su Ji-Ying,Song Lu-Xi,Xiao Chao,Li Xiao

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1219903

Reference31 articles.

1. Swerdlow S. International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

2. Myelodysplastic Syndromes, Version 2.2015

3. Clinical Effect of Point Mutations in Myelodysplastic Syndromes

4. Myelodysplastic syndromes: the role of the immune system in pathogenesis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway;Hematological Oncology;2023-09-15

2. Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes;Current Oncology;2022-09-25

3. Recurrent transcriptional responses in AML and MDS patients treated with decitabine;Experimental Hematology;2022-07

4. Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation;Frontiers in Genetics;2021-01-27

5. The emergence of drug resistance to targeted cancer therapies: Clinical evidence;Drug Resistance Updates;2019-12